Innovent Biologics, Inc. (IVBXF)
OTCMKTS
· Delayed Price · Currency is USD
10.50
+0.26 (2.54%)
Jul 3, 2025, 9:30 AM EDT
Innovent Biologics Employees
Innovent Biologics had 5,659 employees as of December 31, 2024. The number of employees increased by 787 or 16.15% compared to the previous year.
Employees
5,659
Change (1Y)
787
Growth (1Y)
16.15%
Revenue / Employee
$228,102
Profits / Employee
-$2,291
Market Cap
18.77B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Endo, Inc. | 3,116 |
| Elite Pharmaceuticals | 64 |
| Tian'an Technology Group | 8 |
| Glass House Brands | 374 |
| American Oncology Network | 1,914 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 9 |
| Silence Therapeutics | 116 |
Innovent Biologics News
- 6 days ago - Novo Nordisk, Eli Lilly face first major obesity drug rival in China as Innovent gains approval for mazdutide - Seeking Alpha
- 7 days ago - Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms - PRNewsWire
- 9 days ago - Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management - PRNewsWire
- 12 days ago - Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions - PRNewsWire
- 13 days ago - Neutral On Innovent Biologics: Hard To Justify Its Premium - Seeking Alpha
- 15 days ago - Multiple Research Results from Innovent's General Biomedicine Pipeline to be Showcased at the ADA 85th Scientific Sessions - PRNewsWire
- 21 days ago - Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China - PRNewsWire
- 24 days ago - Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA's 85th Scientific Sessions - PRNewsWire